Kamalakar Surineni, MD, MPH,FAPA

Professional Background

Dr. Kamalakar Surineni is a board-certified psychiatrist (ABPN) and Clinical Assistant Professor. He serves as the attending supervisor for the KU Geriatric Psychiatry Services. He provides both inpatient and outpatient mental health care for older Kansans, including outpatient services to the VC-HOPE PACE® program.

Deeply committed to medical education, Dr. Surineni actively mentors psychiatry residents and medical students while championing expanded mental health outreach in underserved communities. He is widely published and serves as an investigator in multiple clinical trials focused on dementia and other psychiatric and medical conditions.

He also serves as the President-Elect of the Kansas Psychiatric Society and holds several key academic roles within the American Psychiatric Association (APA), including service on the Maintenance of Certification Committee (ABPN), Access to Care Committee, Nominations Committee, and Health Disparities Committee. Beyond his academic leadership, he contributes to healthcare policy as a member of the Kansas Drug Utilization Review Board (KDHE) and the Governor’s Aging Subcommittee (KDADS), where he helps advance initiatives that improve mental health services for older Kansans.

Dr. Surineni has a long-standing commitment to volunteerism, having served at The Kitchen Clinic in Springfield, MO, during his master's in public health, and at Duchesne Clinic in Kansas City, MO, while working at the Kansas City VA. Currently, he volunteers with the Disaster Mental Health Services (DMH) of the American Red Cross, providing free mental health consultations to disaster survivors across Kansas and Oklahoma region.

• MBBS, Medicine, Kakatiya Medical College, India
• MPH, Public Health (Epidemiology, Biostatistics), Missouri State University, Springfield, MO
• Residency, Psychiatry , University of Kansas Medical Center, Wichita, Kansas

• Kamalakar Surineni, Kansas State Board of Healing Arts

• American Psychiatric Association, Nominations committee, Member, 2025 - Present
• American Psychiatric Association, Early Career Psychiatrist Representative , Member, 2024 - Present
• American Psychiatric Association, Rules Committee , Member, 2024 - Present
• American Association for Geriatric Psychiatry, Member, 2023 - Present
• American Neuropsychiatric Association, Member, 2023 - Present
• American Psychiatric Association, APA- Federal Advocacy Representative of KPS, 2023 - 2023
• American Medical Association , Member, 2017 - Present

• Metformin in Alzheimer’s dementia Prevention (MAP) Study. Dr Surineni is helping with in person clinical trial patient visits, Physical Examinations and laboratory interpretation and management. , National Institutes of Health (NIH) through the National Institute on Aging (NIA)
• Kansas University Alzheimer's Disease Center Registry, Dr Surineni is helping with screening for eligible patients, in person clinical trial patient visits, Physical Examinations and laboratory interpretation and management. , Kansas University Alzheimer's Disease Center
• A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-Finding Study with an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease (BAN2401-G000-201): Closed for active enrollment; Dr Surineni is helping with followup clinical trial appointments. , Eisai Inc
• Ranolazine in ALS: safety, and effect on cramps, function and quality of life., University of Kansas

• Li Susan, Surineni Kamalakar. 2025. Falls in Hospitalized Patients and Preventive Strategies: A Narrative Review. The American Journal of Geriatric Psychiatry: Open Science, Education, and Practice, 5, 1-9. https://doi.org/10.1016/j.osep.2024.10.004
• Pirtle Jimmie L, Hickman Melissa D, Boinpelly Varun C, Surineni Kamalakar, Thakur Hemant K, Grasing Kenneth W. 2019. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study. Pharmacology Biochemistry and Behavior, 180, 52-59. https://doi.org/10.1016/j.pbb.2019.02.010
• Li Susan, Surineni Kamalakar, Prabhakaran Nishant. 2025. Cyber-Attacks on Hospital Systems: A Narrative Review. The American Journal of Geriatric Psychiatry: Open Science, Education, and Practice. https://doi.org/10.1016/j.osep.2025.03.002
• Martin Phillip K, Surineni Kamalakar, Schroeder Ryan W, Hilsabeck Robin C, Ayers Gayle Y. 2024. Diagnostic Interviewing and Cognitive Screening, 13-28. https://doi.org/10.1093/med/9780197690024.003.0003
• Surineni Kamalakar, Le Vy, McKaughan Kevin, Fotion Namie. 2025. Use of Paliperidone Long-Acting Injections in Huntington's Disease. Journal of Clinical Psychopharmacology, 45 (3), 293-295. https://doi.org/10.1097/jcp.0000000000001989
• Surineni Kamalakar, Smith Andrew, Glein Rachel, Schrader Nolan. 2025. A Case of Olanzapine Resistance from Heavy Smoking and Clinical Considerations. Kansas Journal of Medicine, 18 (1), 21-22. https://doi.org/10.17161/kjm.vol18.22846
• Surineni Kamalakar, Le Vy, Jones Danielle. 2024. A Case of Oral-Buccal-Lingual Dyskinesia and Neuropsychiatric Symptoms After Prolonged Levetiracetam Exposure. Cureus. https://doi.org/10.7759/cureus.62692
• Le Vy, Wollard Kylee, Lee Ricky, Surineni Kamalakar. 2023. Case of Persistent Post-ictal and Inter-ictal Delirium. Kansas Journal of Medicine, 16 (2), 214-217. https://doi.org/10.17161/kjm.vol16.20116
• Surineni Kamalakar, Muhammad Afzal, Barua Rajath, Parashara Deepak. 2016. Epinephrine-Induced Takotsubo Cardiomyopathy,. https://pmc.ncbi.nlm.nih.gov/articles/PMC6373712/